The subsidiary reached continuous production of organic acids in mid‑2025. The milestone validated all stages of Afyren’s proprietary fermentation process and enabled the company to begin commercial deliveries of bio‑based acids under multi‑year contracts.
“The ramp-up period is a key stage in any industrialization process: it requires mobilizing significant resources for an asset that has not yet reached full capacity,” Nicolas SORDET, CEO of AFYREN, said in a press statement. “It is therefore crucial to anticipate and secure the necessary financing to navigate this phase with confidence. To achieve this, we rely on a balanced mix of grants, debt, and equity, ensuring the strength of our financial structure.”